.jpg "Depomed (NASDAQ: DEPO)")
In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Buy rating on Depomed (NASDAQ: DEPO), with a price target of $9. The company’s shares opened today at $6.57.
Rivkind Koffler commented:
“We note that partner Collegium announced a 9.9% price increase to Nucynta/ER on its call. We reiterate our Buy rating as we see the shares as undervalued.”
According to TipRanks.com, Koffler is a 5-star analyst with an average return of 12.2% and a 46.9% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Adamas Pharmaceuticals, and Eagle Pharmaceuticals.
Depomed has an analyst consensus of Moderate Buy, with a price target consensus of $9.
See today’s analyst top recommended stocks >>
Based on Depomed’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $33.1 million. In comparison, last year the company had a GAAP net loss of $26.74 million.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Depomed, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Newark, CA.
